Protocol No.: COG-ARST1431

Title
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Principal Investigator
Paul, Stephan
Phase
III
Age Group
Both
Applicable Disease Site
Pediatric Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contacts
Jan Rapp
Clinical Trials Manager
Phone: +1 304-293-1229
Carla Corbin, RN, BSN
Nurse Clinician
Phone: +1 304-293-1217
Denise Casino
Clinical Trials Manager
Phone: +1 304-293-0735

View on ClinicalTrials.gov